PRESS RELEASE published on 07/03/2024 at 08:12, 2 years 2 months ago CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities CureVac initiates strategic restructuring to focus on high-value mRNA pipeline opportunities, including workforce reduction and new GSK agreement Oncology Strategic Restructuring CureVac MRNA Pipeline GSK Agreement
PRESS RELEASE published on 07/03/2024 at 08:09, 2 years 2 months ago GSK and CureVac to Restructure Collaboration into New Licensing Agreement GSK and CureVac restructure collaboration into new licensing agreement for mRNA vaccines development, manufacturing, and commercialization globally Licensing Agreement Collaboration GSK MRNA Vaccines CureVac
BRIEF published on 06/24/2024 at 22:10, 2 years 2 months ago CureVac Announces Voting Results of General Meeting Annual General Meeting Voting Results Board Appointments CureVac MRNA
PRESS RELEASE published on 06/24/2024 at 22:05, 2 years 2 months ago CureVac Announces Voting Results of General Meeting CureVac announces voting results of the general meeting, including board appointments and auditor reappointment. Shareholders voted in favor of all proposals Appointments Voting Results General Meeting CureVac Auditor Reappointment
BRIEF published on 05/28/2024 at 13:05, 2 years 3 months ago CureVac Announces Dosing of First Participant in Phase 2 Influenza Study GSK MRNA Technology Phase 2 Study CureVac Influenza Vaccine
PRESS RELEASE published on 05/28/2024 at 13:00, 2 years 3 months ago CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK CureVac initiates Phase 2 study in collaboration with GSK for seasonal influenza vaccine, targeting improved immune responses against influenza B strain GSK Vaccine Development Phase 2 Study CureVac Seasonal Influenza
BRIEF published on 05/23/2024 at 13:05, 2 years 3 months ago CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update Financial Results Business Update Q1 2024 CureVac FDA Fast Track
PRESS RELEASE published on 05/23/2024 at 13:00, 2 years 3 months ago CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update CureVac announces financial results for Q1 2024, reports €300.2 million cash position and updates on organizational restructuring and patent litigations Financial Results Cash Position CureVac Patent Litigation Organizational Redesign
BRIEF published on 04/24/2024 at 13:11, 2 years 4 months ago CureVac Announces 2023 Financial Results and Strategic Business Updates MRNA Technology CureVac Pharmaceutical Collaborations Oncology Vaccines Prophylactic Vaccines
BRIEF published on 04/24/2024 at 13:08, 2 years 4 months ago CureVac Begins Combined Phase 1/2 Study for Avian Influenza H5N1 Vaccine with GSK GSK CureVac Phase 1/2 Study Influenza H5N1 MRNA Vaccine
Published on 09/04/2026 at 23:30, 4 hours 28 minutes ago FutureGen Industries Announces Shares for Debt Settlement
Published on 09/04/2026 at 23:00, 4 hours 58 minutes ago Golden Minerals Announces Management Change and Argentine Project Update
Published on 09/04/2026 at 22:30, 5 hours 28 minutes ago Panther Minerals Closes Brokered Private Placement of $3,000,000
Published on 09/04/2026 at 14:30, 13 hours 28 minutes ago Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF)
Published on 09/04/2026 at 14:00, 13 hours 58 minutes ago Horizon Aircraft Appoints Tom Hearne to Board of Directors and Names Him Audit Committee Chair
Published on 09/04/2026 at 22:10, 5 hours 48 minutes ago Quantinuum to Participate in the Bernstein 23rd Annual Pan-European Strategic Decisions Conference
Published on 09/04/2026 at 19:20, 8 hours 38 minutes ago Dahua Technology Showcases Integrated Smart Living and Innovations at IFA Berlin 2026
Published on 09/04/2026 at 18:50, 9 hours 8 minutes ago A&S Resources secures railway funding of USD$6 Billion to unlock $2.5 trillion iron ore asset
Published on 09/04/2026 at 18:05, 9 hours 53 minutes ago Grundig Unveils New Product Lineup at IFA 2026, Marking a New Phase in Strategic Partnership
Published on 09/04/2026 at 18:57, 9 hours 1 minute ago Disclosure of transactions in own shares from September 1 to September 4, 2026
Published on 09/04/2026 at 17:45, 10 hours 13 minutes ago Declaration of voting rights at the end of August 2026
Published on 09/04/2026 at 17:45, 10 hours 13 minutes ago DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS
Published on 09/04/2026 at 16:00, 11 hours 58 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of July 31, 2026
Published on 09/04/2026 at 16:00, 11 hours 58 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of August 31, 2026
